Blockchain Registration Transaction Record

Clene Announces Key Updates on NIH-Funded Expanded Access Program for CNM-Au8 Compassionate Use in ALS

Clene (CLNN) announces key updates on NIH-funded Expanded Access Program for CNM-Au8 compassionate use in ALS, highlighting the potential impact of the investigational drug in treating neurodegenerative diseases.

Clene Announces Key Updates on NIH-Funded Expanded Access Program for CNM-Au8 Compassionate Use in ALS

This news matters because it highlights the progress and potential impact of Clene's investigational drug CNM-Au8 in providing a treatment option for the ALS community. The positive results from the Phase 2 clinical studies and the NIH-funded EAP demonstrate the company's commitment to improving mitochondrial health and protecting neuronal function in neurodegenerative diseases.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x9f80773085a2e0490fb2a3ca7f7a39547b9ae1aab88ac5616f69085aa53f7183
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintchef9e7P-1c8a13374a60492255228b1da326fa0c